Anavex Life Sciences Corp (AVXL)

[JB3729]

DD - Updated Collection Of Recent Articles And Videos With The Most Recent First:

Go to Anavex.com for press releases and more info on the Company


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122166515
Alzheimer's Disease Breakthrough: Melbourne drug trial achieves amazing results

Videos of patients that have had their Alzheimer's Disease reversed -
http://video.dailytelegraph.com.au/v/455096/Steve-Macfarlane-explains-the-Alzheimers-worldfirst-drug-trial-at-Caulfield-Hospital

http://www.msn.com/en-au/video/w/alzheimers-breakthrough-in-melbourne-drug-trial/vp-BBsbgnI


Point-by-point rebuttal to Fonteneau's attack article.
https://medium.com/@jdlambert/the-anavex-story-for-honest-investors-67e1238d4238

http://www.anavex.com/files/Anavex_Presentation_Fall_2015+.pdf
ANAVEX™ 2-­-73 Increases P300 Amplitude Earlier and 4x Higher than Donepezil
ANAVEX™ 2-­-73 Improves both Accuracy and Reaction Time in the Target Detection Task of the ERP Test


http://seekingalpha.com/article/3672856-anavex-life-sciences-interview-with-dr-stephen-macfarlane
Five out of the 6 cogstate domains showed improvement, with 3 of these showing large effect sizes. The 'one-back' test within cogitate showed an effect size of 1.1 (meaning the standard distribution curve of the results was improved by 1.1 standard deviations, a huge effect size. A published meta-analysis of donepezil's benefit on the same test showed an effect size of 0.28. The significance of this particular change is underlined by the fact that 75% of our sample had already been taking a stable dose of donepezil for at least three months, so the improvements on the Cogitate battery (and on all the other cognitive outcome measures, were achieved over and above the gains our participants might already have achieved through being on donepezil. The same is true for the improvements noted on MMSE and ADCS-ADL, and the EEG markers (of which one ERP was statistically significant). I gather much is being made in certain circles that the remainder of the EEG markers, as well as the MMSE and ADCS-ADL scores failed to achieve statistical significance, but in a 5-week study of 32 patients it would almost have been beyond belief if this were to have been shown to be the case. The study was not powered to demonstrate significance, but the response on certain outcome measures was so marked that significance was achieved anyway (at a level of p=0.001 in the case of the Cogitate one-back task.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118144632
Nice Anavex summary


http://seekingalpha.com/article/3444196-premarket-biotech-digest-axovant-analysis-anavex-gets-grant-pharmacyclis-imbruvica?auth_param=btpbb:1at3j0l:afa85ef47d3b60d78c9840325c93132b&uprof=45
I initiated coverage on AVXL almost a month ago. In the article, I had noted that AVXL appears to be the most interesting Alzheimer's disease ("AD") drug company with the lowest valuation. The potential of the company's lead product candidate, Anavex 2-73, was reconfirmed when it released initial data from a Phase 2a study last month. The data showed early evidence of improving condition in patients with AD.

In AD alone, AVXL has a fair value of $5 per share, after adjusting for risk. If you add the potential in Parkinson's, then the potential value of the stock is even higher. If AVXL's concept is proven in AD, it is very likely that it will be proven in Parkinson's as well. (Note: The $5.00 price target was before the 1 for 4 reverse split. It equates to a $20.00 price target now.)


http://www.marketwatch.com/story/anavex-receives-notice-of-allowance-for-us-patent-application-related-to-anavex-2-73-2015-08-12
NEW YORK, Aug 12, 2015 (GLOBE NEWSWIRE via COMTEX) --

Anavex Life Sciences Corp. ("Anavex" or the "Company") (otcqx:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property (IP) protection until at least 2035. ANAVEX2-73 is the subject of an ongoing Phase 2a clinical trial for the treatment of Alzheimer's disease.


https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1450
Impact on Diagnosis/Treatment of Parkinson’s:
The present study holds potential to impact the way Parkinson’s disease is treated. We aim to develop a new pharmacological approach to boost repair mechanisms and dampen inflammation in the part of the brain that is most affected by Parkinson’s. If this treatment exerts the expected effects, it could slow the progression of the disease.

Next Steps for Development:
If successful, this study will accelerate the translation of pre-clinical findings into the first clinical trial of ANAVEX2-73 as a potential disease-modifying therapy for Parkinson’s disease. ANAVEX2-73 has already been tested for safety and tolerability in humans with positive results.


http://seekingalpha.com/article/3354415-interview-with-dr-christopher-missling-ceo-of-anavex?auth_param=d2ta:1ar4d6c:74ced639ac1ecb22d9cbea5192bcfa90
KKD - So, until you get the patent assigned to you, you cannot begin the Anavex Plus trial, correct?

CM - No. All patents are irrevocably assigned or owned by Anavex.


http://seekingalpha.com/article/3354385-anavex-may-actually-cure-alzheimers


https://au.news.yahoo.com/video/watch/29015798/new-pills-offer-hope-for-alzheimers-sufferers/#page1
"It's like being in the dark and someone switched the light on."


http://www.heraldsun.com.au/news/victorians-first-to-trial-breakthrough-brain-booster-pill/story-fni0fiyv-1227453139615
A PILL to treat Alzheimer’s disease is four times more effective than the current treatment in boosting the brain power of patients.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Prof Macfarlane said.


http://thestockradio.com/otcqx-avxl-anavex-life-sciences-corp-ceo-pres-christopher-missling-2050.html


http://www.anavex.com/
Corporate Presentation - Spring 2015


http://www.endevr.com/dementia/New-drug-might-help-prevent-slow-or-reverse-Alzheimer-s
Findings in a recent peer-reviewed scientific journal reveals that our lead drug, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.